





POLYCYTHEMIA VERA

by the Numbers

Polycythemia vera (PV) is a chronic, incurable blood cancer associated with an overproduction of blood cells in the bone marrow¹



Median age at diagnosis is 60 but can occur at any age⁴



Elevated hematocrit level is associated with a **4X** higher rate of cardiovascular death⁵


Cardiovascular complications account for approximately **40%** of patient deaths⁶

DEFINITIONS

Hematocrit is a measure of the volume percentage of red blood cells in whole blood¹

Phlebotomy is a procedure to remove blood from the body to reduce the concentration of red blood cells¹

Currently there is no cure, and treatment options are limited¹



Median survival varies from **9.1 → 12.6** years with different therapies⁷

Research is underway to help beat the odds and improve the lives of patients with PV

References

1. Leukemia & Lymphoma Society. Polycythemia Vera Facts. June 2012. Available at <http://www.lls.org/content/nationalcontent/resourcecenter/freeducationmaterials/mpd/pdf/polycythemiavera.pdf>.
2. Titmarsh G, Duncombe A, McMullin M, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. *American Journal of Hematology*. 2014;1-7.
3. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy. *Am. J. of Hematol*. 2008;83:491-497.
4. Mayo Clinic. Polycythemia Vera. Available at <http://www.mayoclinic.org/diseases-conditions/polycythemia-vera/basics/causes/con-20031013>.
5. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. *N Engl J Med*. 2013; 368:22-33.
6. Finazzi G and Barbui T. How I treat patients with polycythemia vera. *Blood*. 2007;109(12):5104-5111.
7. Alvarez-Larran A, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. *Blood*. 2012;119(6):1363-1369.
8. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythemia: a complement to the previously published data of the Polycythaemia Vera Study Group. *Br J Haematol*. 1994;86(1):233-235.
9. Barbui T, Finazzi G. Treatment of polycythemia vera. *Haematologica*. 1998;83:143-149.